Diagnos Inc V.ADK

Alternate Symbol(s): DGNOF

Healthcare Medical Devices

DIAGNOS Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for modifying and developing of applications, such as Computer Assisted Retina Analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. Its geographical areas include Canada, the United States, Saudi Arabia, Mexico, Costa Rica and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.

TSXV:ADK - Post by User

Diagnos Inc

<< Previous

Bullboard Posts

Next >>

Post by Betteryear2on Apr 26, 2022 9:53am

133 Views

Post# 34631729

DIAGNOS Extension of its Contract with Novo Nordisk

BROSSARD, Quebec, April 26, 2022 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS”, the “Corporation” or “we”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce the extension of its contract for the follow-up of Diabetic patients under treatment with drugs included in its therapeutic portfolio.

DIAGNOS Announces the Extension of its Contract with Novo Nordisk for the Follow-up of Diabetic Patients Under Treatment with Drugs Included in its Therapeutic Portfolio

<< Previous

Bullboard Posts

Next >>

Silvercorp to expand into Ecuador with C$200M Adventus acquisition